LBA13 Nivolumab and ipilimumab in early-stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): First results from the BELLINI trial

I. Nederlof, Olga I. Isaeva, N. Bakker, Manon de Graaf, R.F. Salgado, Natasja Klioueva, Kristin Van de Vijver, Frederieke van Duijnhoven, E. Kalashnikova, Silvia Willingham, S. Luykx, C.E. Loo, E. Kerver, G.S. Sonke, C.U. Blank, R. Mann, S.C. Linn, Diether Lambrechts, H. Horlings, Marleen Kok